The real concern for your future


Our strategy relies on R&D investments and further growth of our own full-cycle production. We foresee implementation of our plans through three strategic priorities:

  • Securing our positions in the synthesis of active pharmaceutical substances
  • Leadership in the innovative drug creation and expanding the scope of our existing portfolio
  • Diversifying the portfolio with new therapeutic drug groups and formulations